{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:03Z","timestamp":1787008623912,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01 DA048172"],"award-info":[{"award-number":["K01 DA048172"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30 DA011041"],"award-info":[{"award-number":["P30 DA011041"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) elimination is an important global public health goal. However, the United States is not on track to meet the World Health Organization's 2030 targets for HCV elimination. Recently, the White House proposed an HCV elimination plan that includes point-of-care (POC) HCV RNA testing, which is currently in use in many countries but is not approved in the United States. POC HCV RNA testing is crucial for implementing community-based testing and for enabling test-and-treat programs, assessing cure, and monitoring for reinfection. Here, we review the status of POC HCV RNA testing in the United States, discuss factors that are needed for successful implementation, and issue specific public health and policy recommendations that would allow for the use of POC HCV RNA testing to support HCV elimination.<\/jats:p>","DOI":"10.1093\/cid\/ciad503","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T01:11:54Z","timestamp":1692753114000},"page":"1235-1239","source":"Crossref","is-referenced-by-count":12,"title":["The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6363-2839","authenticated-orcid":false,"given":"Shashi N","family":"Kapadia","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Weill Cornell Medicine , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9426-2869","authenticated-orcid":false,"given":"Ashly E","family":"Jordan","sequence":"additional","affiliation":[{"name":"Center for Drug Use and HIV\/HCV Research , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J","family":"Eckhardt","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, New York University School of Medicine , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Perlman","sequence":"additional","affiliation":[{"name":"Center for Drug Use and HIV\/HCV Research , New York, New York , USA"},{"name":"Division of Infectious Diseases, Icahn School of Medicine at Mt Sinai , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,27]]},"reference":[{"key":"2024051423572845100_ciad503-B1"},{"key":"2024051423572845100_ciad503-B2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/liv.13949","article-title":"Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework","volume":"39","author":"Day","year":"2019","journal-title":"Liver Int"},{"key":"2024051423572845100_ciad503-B3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"key":"2024051423572845100_ciad503-B4","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/jvh.13399","article-title":"Loss to follow-up in the hepatitis C care cascade: a substantial problem but opportunity for micro-elimination","volume":"27","author":"van Dijk","year":"2020","journal-title":"J Viral Hepat"},{"key":"2024051423572845100_ciad503-B5","doi-asserted-by":"crossref","first-page":"e1290","DOI":"10.1093\/cid\/ciab261","article-title":"Hepatitis C care cascades for 3 populations at high risk: low-income trans women, young people who inject drugs, and men who have sex with men and inject drugs","volume":"73","author":"Facente","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024051423572845100_ciad503-B6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/jvh.13437","article-title":"Hepatitis C testing and treatment uptake among young people who use opioids in New York City: a cross-sectional study","volume":"28","author":"Kapadia","year":"2021","journal-title":"J Viral Hepat"},{"key":"2024051423572845100_ciad503-B7","doi-asserted-by":"crossref","first-page":"e1112","DOI":"10.1093\/cid\/ciab779","article-title":"Projected long-term impact of the coronavirus disease 2019 (COVID-19) pandemic on hepatitis C outcomes in the United States: a modeling study","volume":"75","author":"Barocas","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024051423572845100_ciad503-B8","doi-asserted-by":"crossref","first-page":"103889","DOI":"10.1016\/j.drugpo.2022.103889","article-title":"A stakeholder-driven framework for measuring potential change in the health risks of people who inject drugs (PWID) during the COVID-19 pandemic","volume":"110","author":"Bradley","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2024051423572845100_ciad503-B9","doi-asserted-by":"crossref","first-page":"766","DOI":"10.15585\/mmwr.mm7228a2","article-title":"Updated operational guidance for implementing CDC\u2019s recommendations on testing for hepatitis C virus infection","volume":"72","author":"Cartwright","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024051423572845100_ciad503-B10","doi-asserted-by":"crossref","first-page":"103917","DOI":"10.1016\/j.drugpo.2022.103917","article-title":"Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: a systematic review and meta-analysis","volume":"111","author":"Cunningham","year":"2023","journal-title":"Int J Drug Policy"},{"issue":"Suppl 5","key":"2024051423572845100_ciad503-B11","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.1093\/infdis\/jiz659","article-title":"Hepatitis C virus incidence in a cohort in medication-assisted treatment for opioid use disorder in New York City","volume":"222","author":"Jordan","year":"2020","journal-title":"J Infect Dis"},{"key":"2024051423572845100_ciad503-B12","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.939325","article-title":"Optimizing treatment for combined midshaft clavicle fracture and acromioclavicular joint injury: a case study highlighting the efficacy of Knowles pin fixation","volume":"24","author":"Shih","year":"2023","journal-title":"Am J Case Rep"},{"key":"2024051423572845100_ciad503-B13","doi-asserted-by":"crossref","first-page":"103345","DOI":"10.1016\/j.drugpo.2021.103345","article-title":"Implementing opt-out hepatitis C virus (HCV) screening in Canadian provincial prisons: a model-based cost-effectiveness analysis","volume":"96","author":"Duchesne","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2024051423572845100_ciad503-B14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/liv.15123","article-title":"Cost-effectiveness analysis of hepatitis C virus (HCV) point-of-care assay for HCV screening","volume":"42","author":"Koo","year":"2022","journal-title":"Liver Int"},{"key":"2024051423572845100_ciad503-B15"},{"key":"2024051423572845100_ciad503-B16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256883","article-title":"Public investments in the development of GeneXpert molecular diagnostic technology","volume":"16","author":"Gotham","year":"2021","journal-title":"PLoS One"},{"key":"2024051423572845100_ciad503-B17"},{"key":"2024051423572845100_ciad503-B18","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2023.3692","article-title":"A national hepatitis C elimination program in the United States: a historic opportunity","volume":"329","author":"Fleurence","year":"2023","journal-title":"JAMA"},{"key":"2024051423572845100_ciad503-B19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/infdis\/jiac049","article-title":"Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of hepatitis C virus RNA: a systematic review","volume":"226","author":"Catlett","year":"2022","journal-title":"J Infect Dis"},{"key":"2024051423572845100_ciad503-B20","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/apt.16953","article-title":"Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial","volume":"55","author":"Byrne","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2024051423572845100_ciad503-B21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/add.16139","article-title":"Commentary on Iversen et al.: adapting public health surveillance and monitoring to reflect how DAAs are changing the epidemiology of hepatitis C virus infection","volume":"118","author":"Jordan","year":"2023","journal-title":"Addiction"},{"key":"2024051423572845100_ciad503-B22","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1111\/liv.14983","article-title":"Outcomes of the CT2 study: a \u201cone-stop-shop\u201d for community-based hepatitis C testing and treatment in Yangon, Myanmar","volume":"41","author":"Draper","year":"2021","journal-title":"Liver Int"},{"key":"2024051423572845100_ciad503-B23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12954-023-00780-3","article-title":"Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs","volume":"20","author":"Hassan","year":"2023","journal-title":"Harm Reduct J"},{"key":"2024051423572845100_ciad503-B24","first-page":"100490","article-title":"Rapid hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study","volume":"22","author":"Lettner","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2024051423572845100_ciad503-B25","doi-asserted-by":"crossref","first-page":"102608","DOI":"10.1016\/j.drugpo.2019.102608","article-title":"Time matters: point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England","volume":"75","author":"Mohamed","year":"2020","journal-title":"Int J Drug Policy"},{"key":"2024051423572845100_ciad503-B26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jhep.2023.04.019","article-title":"A \u201cone-stop-shop\u201d point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study","volume":"79","author":"Sheehan","year":"2023","journal-title":"J Hepatol"},{"key":"2024051423572845100_ciad503-B27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/jvh.13268","article-title":"A same day \u201ctest and treat\u201d model for chronic HCV and HBV infection: results from two community-based pilot studies in Egypt","volume":"27","author":"Shiha","year":"2020","journal-title":"J Viral Hepat"},{"key":"2024051423572845100_ciad503-B28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2468-1253(22)00346-6","article-title":"Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis","volume":"8","author":"Trickey","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024051423572845100_ciad503-B29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024051423572845100_ciad503-B30","first-page":"628","article-title":"Rapid treatment initiation for hepatitis C virus infection: potential benefits, current limitations, and real-world examples","volume":"18","author":"Finbraten","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2024051423572845100_ciad503-B31"},{"key":"2024051423572845100_ciad503-B32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12954-023-00759-0","article-title":"A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa","volume":"20","author":"Saayman","year":"2023","journal-title":"Harm Reduct J"},{"key":"2024051423572845100_ciad503-B33","doi-asserted-by":"crossref","first-page":"103982","DOI":"10.1016\/j.drugpo.2023.103982","article-title":"Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: the TEMPO pilot study","volume":"114","author":"Grebely","year":"2023","journal-title":"Int J Drug Policy"},{"key":"2024051423572845100_ciad503-B34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/jvh.13798","article-title":"Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days","volume":"30","author":"Debette-Gratien","year":"2023","journal-title":"J Viral Hepat"},{"key":"2024051423572845100_ciad503-B35","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/liv.15266","article-title":"Peer support in small towns: a decentralized mobile hepatitis C virus clinic for people who inject drugs","volume":"42","author":"Midgard","year":"2022","journal-title":"Liver Int"},{"key":"2024051423572845100_ciad503-B36"},{"key":"2024051423572845100_ciad503-B37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S2468-1253(22)00355-7","article-title":"A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia","volume":"8","author":"Grebely","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024051423572845100_ciad503-B38","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/00333549221101381","article-title":"Enhancing surveillance protocols for acute hepatitis C virus infection, Utah, 2014\u20132019","volume":"138","author":"Lewis","year":"2023","journal-title":"Public Health Rep"},{"key":"2024051423572845100_ciad503-B39","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy144","article-title":"Effect of hepatocellular carcinoma on mortality among individuals with hepatitis B or hepatitis C infection in New York City, 2001\u20132012","volume":"5","author":"Moore","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2024051423572845100_ciad503-B40","doi-asserted-by":"crossref","DOI":"10.2196\/38196","article-title":"The importance of incorporating at-home testing into SARS-CoV-2 point prevalence estimates: findings from a US National Cohort, February 2022","volume":"8","author":"Qasmieh","year":"2022","journal-title":"JMIR Public Health Surveill"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad503\/51559774\/ciad503.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/5\/1235\/57636984\/ciad503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/5\/1235\/57636984\/ciad503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T19:57:55Z","timestamp":1715716675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/5\/1235\/7252336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,27]]},"published-print":{"date-parts":[[2024,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad503","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,15]]},"published":{"date-parts":[[2023,8,27]]}}}